New research published in Annals of the Rheumatic Diseases suggests inhibition of phosphodiesterase 4 (PDE4) could have disease-modifying antifibrotic effects in systemic sclerosis (SSc), particularly ...

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for ...

CHICAGO -- Adding the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Daliresp) to metformin may help obese women with polycystic ovarian syndrome (PCOS) shed pounds and improve other metabolic ...

Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting its ability to significantly reduce ...

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with the ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...

NEW ORLEANS -- A novel lower-concentration topical formulation of the PDE4 inhibitor roflumilast produced rapid improvement in mild to moderate atopic dermatitis (AD) in children and adults, two ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...